Cytek Biosciences (NASDAQ:CTKB – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. Cytek Biosciences had a negative net margin of 8.88% and a negative return on equity of 3.75%. The business had revenue of $51.50 million during the quarter, compared to analyst estimates of $50.63 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. Cytek Biosciences updated its FY 2024 guidance to EPS.
Cytek Biosciences Price Performance
Shares of CTKB stock traded up $1.55 on Wednesday, hitting $6.99. The company’s stock had a trading volume of 2,421,129 shares, compared to its average volume of 678,375. The stock has a market capitalization of $919.25 million, a price-to-earnings ratio of -50.50 and a beta of 1.32. Cytek Biosciences has a fifty-two week low of $3.80 and a fifty-two week high of $9.87. The firm’s fifty day moving average price is $5.20 and its 200-day moving average price is $5.64.
Analyst Ratings Changes
Separately, Piper Sandler dropped their price target on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th.
About Cytek Biosciences
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Featured Stories
- Five stocks we like better than Cytek Biosciences
- Investing in the High PE Growth Stocks
- What a Trump Win Looks Like for the Market Now and Into 2025
- Election Stocks: How Elections Affect the Stock Market
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.